Aspen Neuroscience, Inc., a San Diego, CA-based private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), closed its $147.5m Series B funding round.
GV, LYFE Capital and Revelation Partners co-led the round with participation from additional new investors Newton Investment Management, Singapore-based global investor EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment and others. The raise included investments from Series A/Seed investment teams including OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Section32 and Alexandria Venture Investments. As part of the financing, Doug Fisher of Revelation Partners will join the board of directors.
The company intends to use the funds to conduct the planned studies of its lead product candidate for Parkinson’s disease, ANPD001, including its patient Screening Cohort study and the upcoming Phase 1/2a clinical trial, post-IND submission to FDA.
Aspen Neuroscience is a development stage, private biotechnology company focused on personalized (autologous) cell therapies. The company is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD) and extending across the brain and affected organs. An iPSC platform company, Aspen combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments. The company has developed a platform to create and characterize pluripotent-derived cell medicines, which includes in-house bioinformatics, manufacturing and QC.
FinSMEs
09/05/2022